Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving Humana Inc. and its officers or directors [1] Group 1: Legal Issues - The U.S. Department of Justice filed a False Claims Act complaint against Humana and other health insurance companies, alleging that from 2016 to at least 2021, they paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [3] - Following the DOJ's lawsuit announcement, Humana's stock price decreased by $6.20 per share, or 2.36%, closing at $256.04 on May 1, 2025 [3] Group 2: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Humana Inc.  (“Humana” or the “Company”) (NYSE: HUM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Humana and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 1, 2025, the U.S. ...

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Humana Inc. (“Humana” or the “Company”) (NYSE:HUM). The investigation concerns whether Humana and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On May 1, 2025, the U.S. Department of Justice filed a complaint against insurance broker organizations, including Humana, alleging t ...

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE: HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Humana and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May 1, 2025, the U.S. Department of ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. (“Humana” or the “Company”) (NYSE: HUM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Humana and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 1, 2025, the U.S. De ...

Humana Inc. (HUM) reported first-quarter 2025 adjusted earnings of $11.58 per share, which outpaced the Zacks Consensus Estimate by 16%. The bottom line soared 60.2% year over year. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Adjusted revenues improved 9.5% year over year to $32.1 billion. However, the top line missed the consensus mark by 0.3%. The quarterly results benefited on the back of strong premiums resulting from an expanding customer base in stand-alone prescription drug ...

Humana (HUM) reported $32.11 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 9.5%. EPS of $11.58 for the same period compares to $7.23 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $32.22 billion, representing a surprise of -0.33%. The company delivered an EPS surprise of +16.03%, with the consensus EPS estimate being $9.98.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how t ...

Financial Performance - Humana's net income for Q1 2025 was $1.2 billion, or $10.30 per diluted share, compared to $0.7 billion, or $6.11 per diluted share in Q1 2024, reflecting a 68.1% increase [127]. - Total revenues increased by 8.4% to $32.1 billion in Q1 2025, up from $29.6 billion in Q1 2024, driven by an 8.0% rise in insurance premiums [133]. - The benefit ratio improved to 87.0% in Q1 2025 from 88.9% in Q1 2024, indicating better underwriting profitability [133]. - Operating costs rose by 11.1% to $3.4 billion in Q1 2025, compared to $3.0 billion in Q1 2024, reflecting increased administrative spending [133]. - Consolidated premiums revenue increased by $2.3 billion, or 8.0%, from $28.3 billion in the 2024 quarter to $30.5 billion in the 2025 quarter, driven by higher per member Medicare premiums and membership growth in stand-alone PDP and state-based contracts [135]. - Consolidated services revenue rose by $272 million, or 25.6%, from $1.1 billion in the 2024 quarter to $1.3 billion in the 2025 quarter, primarily due to growth in the primary care business [136]. - Consolidated benefits expense increased by $1.4 billion, or 5.6%, from $25.1 billion in the 2024 quarter to $26.5 billion in the 2025 quarter, with the consolidated benefit ratio decreasing by 190 basis points to 87.0% [138]. Membership and Segments - Approximately 3.5 million, or 67%, of individual Medicare Advantage members were in value-based relationships as of March 31, 2025, down from 69% a year earlier [126]. - Individual Medicare Advantage membership decreased by 333,100 members, or 6.0%, from March 31, 2024, to March 31, 2025, including a net decrease of 123,100 D-SNP members [149]. - Group Medicare Advantage membership increased by 21,100 members, or 3.8%, from March 31, 2024, to March 31, 2025 [150]. - State-based contracts and other membership increased by 346,700 members, or 27.5%, reflecting new contracts implemented in Oklahoma and Indiana [151]. - The CenterWell segment's revenue grew by 37.5% to $1.1 billion in Q1 2025, up from $0.8 billion in Q1 2024, highlighting strong performance in healthcare services [133]. - CenterWell segment income from operations increased by $0.1 billion, or 39.0%, from $0.3 billion in the 2024 quarter to $0.4 billion in the 2025 quarter [158]. - CenterWell services revenue increased by $0.3 billion, or 37.5%, from $0.8 billion in the 2024 quarter to $1.1 billion in the 2025 quarter, primarily due to growth in the primary care business [159]. Tax and Investment - The effective tax rate decreased slightly to 24.6% in Q1 2025 from 25.3% in Q1 2024, reflecting changes in tax liabilities [133]. - Investment income decreased by 8.3% to $264 million in Q1 2025, down from $288 million in Q1 2024, indicating challenges in investment performance [133]. - Investment income decreased by $24 million, or 8.3%, from $288 million in the 2024 quarter to $264 million in the 2025 quarter, mainly due to lower interest income on debt securities [137]. - The average duration of the investment portfolio was approximately 3.4 years as of March 31, 2025, indicating sensitivity to interest rate changes [191]. - The company experienced a net unrealized loss position of $1.1 billion on its investment portfolio as of March 31, 2025, down from a loss of $1.4 billion at December 31, 2024 [190]. Cash Flow and Capital Management - Cash and cash equivalents increased to approximately $4.3 billion at March 31, 2025, up from $2.2 billion at December 31, 2024 [163]. - Net cash provided by operating activities decreased to $331 million in the 2025 quarter from $423 million in the 2024 quarter, primarily due to unfavorable working capital impacts [164]. - Total net receivables rose to $4.459 billion at March 31, 2025, compared to $2.704 billion at December 31, 2024, reflecting higher Medicare premiums and membership growth [166]. - Total net capital expenditures, excluding acquisitions, were $95 million in the 2025 quarter, down from $177 million in the 2024 quarter [168]. - The company issued $750 million of 5.550% unsecured senior notes due May 1, 2035, and net proceeds from these offerings were $1.481 billion [171]. - The company repurchased common shares for $702 million in the 2024 quarter and paid dividends of $108 million in the 2025 quarter [176][177]. - Aggregate statutory capital and surplus of state-regulated subsidiaries was approximately $13.2 billion, exceeding minimum regulatory requirements of $11.4 billion [187]. - Future liquidity sources are expected to be adequate for ongoing operations, acquisitions, and capital expenditures for at least the next twelve months [182]. Strategic Focus - Humana's strategy focuses on integrated care delivery, aiming for long-term growth in membership and earnings through enhanced member engagement and data analytics [126]. - Charges related to value creation initiatives amounted to $24 million in Q1 2025, compared to $29 million in Q1 2024, primarily due to asset impairments and workforce optimization [119].

Humana (HUM) came out with quarterly earnings of $11.58 per share, beating the Zacks Consensus Estimate of $9.98 per share. This compares to earnings of $7.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.03%. A quarter ago, it was expected that this health insurer would post a loss of $2.24 per share when it actually produced a loss of $2.16, delivering a surprise of 3.57%.Over the last four quarters, the company has sur ...

Humana (HUM) Q1 2025 Earnings Call April 30, 2025 08:00 AM ET Company Participants Lisa Stoner - Vice President-Investor RelationsJames Rechtin - President & CEOCeleste Mellet - CFOBen Hendrix - Vice PresidentGeorge Renaudin - President of Medicare & Medicaid and DirectorAndrew Mok - DirectorA.J. Rice - Managing DirectorJoshua Raskin - Partner - Managed Care & ProvidersLance Wilkes - Managing DirectorLisa Gill - Managing DirectorDavid Windley - Managing Director Conference Call Participants Sarah James - An ...